The high prescription rate of ACE inhibitor/ARB in the Biosignature CAD cohort reflects the improvement of evidence-based treatment in CV disease, which is also essential to the improvement of long-term outcome in high-risk CAD patients. This evidence concerns the gene ACE and coronary artery disorder.